Why is Astrazeneca Phar falling/rising?

As of 07-Aug, Astrazeneca Pharma India Ltd is experiencing a decline in its stock price, currently at 8,728.50, reflecting a decrease of 104.9 points or 1.19%. The stock has underperformed its sector by 2.05% today and has been on a downward trend for the last three days, accumulating a total decline of 2.95% during this period. Despite a strong year-to-date return of 19.00% and a one-year return of 22.42%, the stock has shown weakness in the short term, with a 5.10% drop over the past week and a 4.39% decline over the past month. The stock's delivery volume has also significantly decreased, falling by 68.47% against the five-day average, indicating reduced investor participation.
In the broader market context, Astrazeneca's recent performance contrasts with the Sensex, which has only declined by 0.69% over the past week. While the company has demonstrated strong management efficiency and positive financial results, including an 88.82% growth in net profit and consistent returns over the last three years, concerns about its high valuation and poor long-term growth prospects may be contributing to the current price decline. The stock's high Price to Book Value ratio and a PEG ratio of 3.1 suggest that it is trading at a premium compared to its peers, which could be influencing investor sentiment negatively in the short term.